Abstract
Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A (GLA) gene leading to markedly decreased or absent α-GalA enzyme activity [1, 2] . The enzymatic defect leads to glycosphingolipid accumulation in plasma, urine and tissue lysosomes. The resulting clinical manifestations include kidney and heart failure, cerebrovascular disease and premature demise. Males are more severely affected than female heterozygotes, whose manifestations can range from asymptomatic to rarely as severely affected as males [1, 2] .
Currently, the diagnosis of affected males involves the demonstration of markedly decreased α-GalA activity in plasma, leucocytes or dried blood spots (DBS), which can be confirmed by GLA mutation analysis [1] . However, due to random Xchromosomal inactivation, at least 40% of GLA-mutation confirmed heterozygotes have normal or slightly decreased α-GalA activity requiring GLA sequencing to confirm heterozygosity [2] [3] [4] .
The phenotypic heterogeneity also complicates the clinical diagnosis of FD in females. There are two major subtypes, the Type 1 "Classic" and the Type 2 "LaterOnset" phenotypes [4] . Affected males with the Type 2 phenotype have residual α-GalA activity, later-onset cardiac and/or renal disease, and lack the major early-onset classical manifestations, including angiokeratoma, acroparesthesias, hypohidrosis, and the ocular abnormalities [5] [6] [7] . Even genetic testing of patients at-risk or suspicious for FD has been compromised by the recently recognized occurrence of various benign missense mutations [8] [9] [10] .
Previously, increased plasma or urine levels of globotriaosylceramide (Gb3) were used to help identify heterozygosity, but its analysis is laborious and multi-procedural A C C E P T E D M A N U S C R I P T
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5 [11] . More recently, the easier measurement of its deacylated form, globotriaosylsphingosine (LysoGb3) has become appreciated as a novel diagnostic tool that can classify Classic and Later-Onset males [12, 13] .
Here, we report three unrelated heterozygotes among the FD patients treated or followed at the University Hospital Zurich with increased LysoGb3, whereas their leukocyte α-GalA activities were in the normal range. In these women, the serum LysoGb3 levels were useful diagnostic markers to identify heterozygotes who should be evaluated for treatment.
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Methods

Patients and clinical work-up
This study was conducted in accordance with the principles of the Helsinki Declaration. All patients signed a written informed consent. All authors have read and approved the manuscript.
Between January 2014 and December 2016, blood for biobanking was drawn from 61 consecutive FD patients (36 females, 59%) at the University Hospital Zurich, Zurich, Switzerland, all with a GLA-mutation confirmed diagnosis, who presented for routine annual examinations at our FD center. In 11 of these patients (5 females), kidney biopsies had been performed, all of which had the typical FD pathology including the prominent Gb3 accumulation in vascular endothelial, interstitial and mesangial cells, and in particular, in podocytes ( Fig. 1) [14] . For serum LysoGb3 levels, blood samples were centrifuged and serum was immediately frozen at −80°C. All patients had a comprehensive work-up, including medical history, cardiac, renal, and neurological evaluations. In this retrospective cohort study, all clinical and routine laboratory results including α-GalA activities were obtained from the patients` medical records. α-GalA activities were originally determined at the time of diagnosis in the males and mutation analyses were performed in all females. For this study, we screened the 18 heterozygotes who previously had a documented α-GalA activity assay at the original diagnosis. For these heterozygotes, we determined the serum LysoGb3 levels.
Phenotyping
Phenotyping was based on GLA mutation type: frame-shift, nonsense, consensus splice-site mutations, large insertions and deletions, and some missense mutations, expression assays were evaluated to determine the mutation's phenotype [7, 8] .
LysoGb3 measurement
Serum LysoGb3 levels were measured by highly-sensitive electrospray ionization liquid chromatography tandem mass spectrometry (ESI LC-MS/MS) on a Shimadzu 8050 class I medical device using an adapted method from Gold et al [15] . A 7-point serum calibrator and an internal standard for LysoGb3 quantification (covering the analytic range from 0-120 ng/mL; lower limit of quantification: 0.3 ng/mL), and three calibrator levels (3, 30 and 100 ng/mL) for quality control were used (ARCHIMED Life Science GmbH, Vienna, Austria; www.archimedlife.com). 
Fabry disease diagnosis in three female patients with normal α-GalA activity
In our study cohort of 61 patients, there were 36 GLA-mutation confirmed heterozygotes. Of these, 18 previously had α-GalA activity determinations, and of these, three had normal α-GalA activities and increased serum LysoGb3 levels, as described in detail below:
Female 1 was 55 years old when she was admitted to the hospital with her third cryptogenic stroke, the first having occurred when she was 50 years old. At initial examination, the patient also described burning sensations in her hands and feet and an inability to sweat. Her son died at 28 years old from recurrent epileptic seizures.
He also complained of burning paresthesias in his hands and feet. Her mother died at 78 years; her father died of a myocardial infarction at the age of 65 years.
Her clinical examination revealed a few angiokeratomas on her trunk, and a slit-lamp examination revealed the characteristic cornea verticillata. Laboratory studies demonstrated normal kidney function and microalbuminuria (urinary albumin/creatinine 4.2 mg/mmol). GLA mutation analysis identified GLA pathologic missense mutation c.796G>T (p.Asp266Tyr) which made her heterozygote diagnosis. This previously reported mutation causes the Classic phenotype [16] .
Female 2 was diagnosed with FD at 39 years of age by family mutation screening.
Her asymptomatic daughter was incidentally found to have proteinuria at 11 years. 
Clinical and biochemical parameters of two female patients with normal α-galactosidase activity and normal LysoGb3 levels.
Two of the 18 females who had α-GalA activity determinations, had normal α-GalA activities and normal serum LysoGb3 levels. Their clinical and biochemical findings are summarized in the Supplementary Table A1 (Females 4 and 5) . These females were diagnosed by family screening.
Clinical and biochemical findings of 13 female patients with reduced α-
GalA activities and increased LysoGb3 levels.
Thirteen of the 18 females, who had α-GalA activity determinations, had reduced α-GalA activities and increased serum LysoGb3 levels. Their clinical and biochemical findings are summarized in Table A1 (Females 6-18). Two of these females were diagnosed with FD as index patients (Females 6 and 12), the other 11 by family screening. The LysoGb3 levels were increased in all these patients with reduced α-GalA activities.
Discussion
We identified three of 18 females with GLA-mutation confirmed FD in whom their α-GalA activities were normal, however, their serum LysoGb3 levels were markedly increased (Table 1) . In FD heterozygotes, the α-GalA activities are often borderline normal or normal due to random X-chromosomal inactivation [3] . Our findings suggest that this biomarker may improve initial diagnose of clinically relevant FD, particularly in female patients. These findings relate to which females should be evaluated for treatment. However, invasive biopsies may not be feasible or acceptable in many heterozygotes [17] . In heterozygotes from classic families, the serum LysoGb3 may serve as a marker of tissue involvement to evaluate the need of treatment. Although, normal
Importantly, the initiation of treatment is
LysoGb3 does not necessarily mean that there is no need for treatment, as the clinical manifestations indicate therapeutic intervention.
Different methods have been used to measure LysoGb3 including LC-MS/MS.
Quality control materials and inter-laboratory testing are required to standardize LysoGb3 measurements among laboratories. This will permit composition of results among laboratories in order to further evaluate the potential use of this marker particularly in patients with the Later-Onset phenotype to improve its diagnostic utility, need for treatment, and therapeutic monitoring.
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Certainly, therapeutic decisions are not made by biomarker levels only and extensive clinical characterization using a multidisciplinary approach, a detailed family history and knowledge of previously reported phenotypic descriptions of the specific GLA mutation are of utmost importance to identify the phenotype and disease severity. Among our females, two had both normal α-GalA activities and normal LysoGb3 levels, which emphasizes the need for further evaluation beyond the use of biomarkers. As previously reported, many heterozygotes from families with the Later-Onset phenotype will have no FD manifestations and no serum LysoGb3 accumulation [12] . For example, the female, who had a mutation resulting in the Later-Onset phenotype, had normal LysoGb3 and would have been misdiagnosed by the biomarker (Supplemental Table, Higher magnification of the podocyte shows lysosomes packed with storage material.
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